Cost-effectiveness of mammographic screening in Australia

Carter, Rob, Glasziou, Paul, van Oortmarssen, Gerrit, de Koning, Harry, Stevenson, Chris, Salkeld, Glenn and Boer, Rob 1993, Cost-effectiveness of mammographic screening in Australia, Australian journal of public health, vol. 17, no. 1, pp. 42-50.

Attached Files
Name Description MIMEType Size Downloads

Title Cost-effectiveness of mammographic screening in Australia
Author(s) Carter, Rob
Glasziou, Paul
van Oortmarssen, Gerrit
de Koning, Harry
Stevenson, ChrisORCID iD for Stevenson, Chris
Salkeld, Glenn
Boer, Rob
Journal name Australian journal of public health
Volume number 17
Issue number 1
Start page 42
End page 50
Total pages 9
Publisher Wiley - Blackwell Publishing Asia
Place of publication Richmond, Vic.
Publication date 1993-03
ISSN 1326-0200
Keyword(s) adult
breast neoplasms
cost-benefit analysis
Summary The purpose of this research was to estimate the cost-effectiveness of mammographic screening to supplement the results of the National Evaluation of Breast Cancer Screening which identified the mortality benefit as the most sensitive parameter. This appraisal used a different computer model, MISCAN, which models the effects of introducing a national screening program into a previously unscreened population, rather than basing estimates on the assumption of a fully established program. For the 40 to 49 age group a mortality reduction of 8 per cent was assumed, rather than the 30 per cent estimate utilised in the National Evaluation. The revised estimate is based on the two Swedish trials (Malmo and WE). New estimates for treatment costs were also incorporated into the MISCAN model. The cost-effectiveness of the policy recommended in the National Evaluation Report, $11 000 per life year saved with two-yearly screening of women over 40, is estimated by the MISCAN model to be $20 300. These differences arise partly from the difference in mortality effects for the 40 to 49 age group, but also from differences inherent in the steady-state and dynamic population approaches to modelling premature deaths averted. The MISCAN results confirm that screening for women over 50 is more cost-effective than screening women under 50. Screening all women aged 50 to 69 every two to three years is reasonable value for money. For women aged 40 to 49 the mortality benefit and cost-effectiveness is less clear, and it would be prudent to allow screening in this group until further evidence is available.
Language eng
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©1993, Wiley
Persistent URL

Document type: Journal Article
Collection: Faculty of Health
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 42 times in TR Web of Science
Scopus Citation Count Cited 39 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 521 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Thu, 09 Aug 2012, 14:57:17 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact